PMID- 29367763
OWN - NLM
STAT- MEDLINE
DCOM- 20190312
LR  - 20240210
IS  - 1476-5594 (Electronic)
IS  - 0950-9232 (Print)
IS  - 0950-9232 (Linking)
VI  - 37
IP  - 15
DP  - 2018 Apr
TI  - Network analysis of SRC-1 reveals a novel transcription factor hub which 
      regulates endocrine resistant breast cancer.
PG  - 2008-2021
LID - 10.1038/s41388-017-0042-x [doi]
AB  - Steroid receptor coactivator 1 (SRC-1) interacts with nuclear receptors and other 
      transcription factors (TFs) to initiate transcriptional networks and regulate 
      downstream genes which enable the cancer cell to evade therapy and metastasise. 
      Here we took a top-down discovery approach to map out the SRC-1 transcriptional 
      network in endocrine resistant breast cancer. First, rapid immunoprecipitation 
      mass spectrometry of endogenous proteins (RIME) was employed to uncover new SRC-1 
      TF partners. Next, RNA sequencing (RNAseq) was undertaken to investigate SRC-1 TF 
      target genes. Molecular and patient-derived xenograft studies confirmed STAT1 as 
      a new SRC-1 TF partner, important in the regulation of a cadre of four SRC-1 
      transcription targets, NFIA, SMAD2, E2F7 and ASCL1. Extended network analysis 
      identified a downstream 79 gene network, the clinical relevance of which was 
      investigated in RNAseq studies from matched primary and local-recurrence tumours 
      from endocrine resistant patients. We propose that SRC-1 can partner with STAT1 
      independently of the estrogen receptor to initiate a transcriptional cascade and 
      control regulation of key endocrine resistant genes.
FAU - Browne, Alacoque L
AU  - Browne AL
AD  - Endocrine Oncology Research Group, Department of Surgery, Royal College of 
      Surgeons, Dublin, Ireland.
FAU - Charmsaz, Sara
AU  - Charmsaz S
AD  - Endocrine Oncology Research Group, Department of Surgery, Royal College of 
      Surgeons, Dublin, Ireland.
FAU - Vareslija, Damir
AU  - Vareslija D
AUID- ORCID: 0000-0003-1000-0357
AD  - Endocrine Oncology Research Group, Department of Surgery, Royal College of 
      Surgeons, Dublin, Ireland.
FAU - Fagan, Ailis
AU  - Fagan A
AD  - Endocrine Oncology Research Group, Department of Surgery, Royal College of 
      Surgeons, Dublin, Ireland.
FAU - Cosgrove, Nicola
AU  - Cosgrove N
AD  - Endocrine Oncology Research Group, Department of Surgery, Royal College of 
      Surgeons, Dublin, Ireland.
FAU - Cocchiglia, Sinead
AU  - Cocchiglia S
AD  - Endocrine Oncology Research Group, Department of Surgery, Royal College of 
      Surgeons, Dublin, Ireland.
FAU - Purcell, Siobhan
AU  - Purcell S
AD  - Endocrine Oncology Research Group, Department of Surgery, Royal College of 
      Surgeons, Dublin, Ireland.
FAU - Ward, Elspeth
AU  - Ward E
AD  - Endocrine Oncology Research Group, Department of Surgery, Royal College of 
      Surgeons, Dublin, Ireland.
FAU - Bane, Fiona
AU  - Bane F
AD  - Endocrine Oncology Research Group, Department of Surgery, Royal College of 
      Surgeons, Dublin, Ireland.
FAU - Hudson, Lance
AU  - Hudson L
AD  - Endocrine Oncology Research Group, Department of Surgery, Royal College of 
      Surgeons, Dublin, Ireland.
FAU - Hill, Arnold D
AU  - Hill AD
AD  - Endocrine Oncology Research Group, Department of Surgery, Royal College of 
      Surgeons, Dublin, Ireland.
FAU - Carroll, Jason S
AU  - Carroll JS
AD  - Cancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.
FAU - Redmond, Aisling M
AU  - Redmond AM
AD  - Cancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.
FAU - Young, Leonie S
AU  - Young LS
AD  - Endocrine Oncology Research Group, Department of Surgery, Royal College of 
      Surgeons, Dublin, Ireland. lyoung@rcsi.ie.
LA  - eng
GR  - 20411/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180125
PL  - England
TA  - Oncogene
JT  - Oncogene
JID - 8711562
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - EC 2.3.1.48 (NCOA1 protein, human)
RN  - EC 2.3.1.48 (Nuclear Receptor Coactivator 1)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Hormonal/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/*genetics/pathology
MH  - Chromatin Assembly and Disassembly/drug effects/genetics
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Female
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic
MH  - *Gene Regulatory Networks/drug effects
MH  - Humans
MH  - MCF-7 Cells
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Microarray Analysis
MH  - Nuclear Receptor Coactivator 1/*physiology
MH  - Transcriptional Activation/genetics
MH  - Transcriptome/drug effects
MH  - Tumor Cells, Cultured
PMC - PMC5895607
COIS- The authors declare that they have no competing interests.
EDAT- 2018/01/26 06:00
MHDA- 2019/03/13 06:00
PMCR- 2018/01/25
CRDT- 2018/01/26 06:00
PHST- 2017/03/23 00:00 [received]
PHST- 2017/09/29 00:00 [accepted]
PHST- 2017/09/26 00:00 [revised]
PHST- 2018/01/26 06:00 [pubmed]
PHST- 2019/03/13 06:00 [medline]
PHST- 2018/01/26 06:00 [entrez]
PHST- 2018/01/25 00:00 [pmc-release]
AID - 10.1038/s41388-017-0042-x [pii]
AID - 42 [pii]
AID - 10.1038/s41388-017-0042-x [doi]
PST - ppublish
SO  - Oncogene. 2018 Apr;37(15):2008-2021. doi: 10.1038/s41388-017-0042-x. Epub 2018 
      Jan 25.